Vol. 4 No. 2 (2024)
Reimbursement Recommendations

Olaparib (Lynparza)

decorative image of the issue cover

Published February 16, 2024

Key Messages

  • CADTH recommends that Lynparza, in combination with abiraterone and prednisone or prednisolone, should be reimbursed by public drug plans for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) if certain conditions are met.
  • Lynparza should only be covered to treat patients with mCRPC who have BRCA mutations, who have not been treated with an androgen receptor pathway inhibitor (ARPi), who have not been treated with a poly-(ADP ribose) polymerase (PARP) inhibitor for mCRPC, and who have not been treated with a CYP-17 inhibitor for mCRPC for more than 4 months. Also, the patients should be in relatively good health.
  • Lynparza, in combination with abiraterone and prednisone or prednisolone, should only be reimbursed if it is prescribed by a clinician with expertise in treating prostate cancer with systemic anticancer therapy and if the costs of both Lynparza and abiraterone are reduced.